|Bid||35.66 x 1100|
|Ask||50.00 x 1200|
|Day's Range||34.39 - 36.05|
|52 Week Range||28.54 - 69.81|
|Beta (3Y Monthly)||1.69|
|PE Ratio (TTM)||28.03|
|Earnings Date||Oct 23, 2018 - Oct 29, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||51.50|
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it Read More...
NEW YORK, Nov. 02, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Here's a roundup of top developments in the biotech space over the last 24 hours. None of the biotech stocks hit 52-week highs in Wednesday's session. Down In The Dumps (Biotech stocks hitting 52-week ...
Anika (ANIK) delivered earnings and revenue surprises of 55.88% and -1.19%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Bedford, Massachusetts-based company said it had net income of 53 cents per share. The medical technology company posted revenue of $26.8 million in the period. Anika shares have decreased 27 percent ...
Anika Therapeutics, Inc. (ANIK) (“Anika” or the “Company”), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, announced that, effective immediately, Anika’s Board of Directors has appointed Susan Vogt as an independent director. Ms. Vogt most recently served as Chief Executive Officer and Director of Aushon Biosystems, a venture-backed company with a novel multiplex immunoassay platform.
Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, Oct. 11, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Anika Therapeutics, Inc. today announced that the Company plans to issue its third-quarter 2018 financial results after the close of the market on Wednesday, October 24, 2018 and hold its investor conference call on the same day, Wednesday, October 24, 2018, at 5:00 p.m.
Ultragenyx (RARE) reports encouraging top-line data from two cohorts of the study evaluating its adeno-associated virus ("AAV") gene therapy candidate -- DTX301.
Arena (ARNA) releases initial optimistic outcomes from a phase IIa study on its pipeline candidate olorinab for treating abdominal pain associated with Crohn's disease.
The FDA has lifted clinical hold on Sarepta's (SRPT) clinical study evaluating the Duchenne muscular dystrophy micro-dystrophin gene therapy program. The clinical hold was placed in July by the FDA.
Alexion Pharmaceuticals (ALXN) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Anika Therapeutics, Inc. , a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid technology, today announced that its President and Chief Executive Officer, Joseph Darling, and Chief Financial Officer, Sylvia Cheung, will participate in a fireside chat at the 2018 Morgan Stanley Global Healthcare Conference on Wednesday, ...
Anika Therapeutics, Inc. (ANIK) (“Anika” or the “Company”), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today announced that Cheryl R. Blanchard, Ph.D., President and Chief Executive Officer of Keratin Biosciences, Inc., has been appointed as a new independent member of the Company’s Board of Directors with a term continuing through the Company’s 2019 Annual Meeting of Stockholders. With Dr. Blanchard’s appointment, the Board of Directors has been expanded to seven directors.
The direct benefit for Anika Therapeutics Inc (NASDAQ:ANIK), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-offRead More...